For a long time, hemp-based solutions were presented in the workplace from the perspective of comfort, recovery, or relaxation. In many HR discussions, the topic seemed to fall under the umbrella of "well-being," alongside meditation, ergonomics, or workplace quality of life programs. But in 2025-2026, the discussion shifted: CBD in the workplace was no longer limited to a promise of improved well-being; it also entered the realm of prevention, compliance, and occupational health.
This shift in the debate can be explained by several converging signals. Between the ANSES alert on cannabidiol, the HAS recommendation on psychoactive substances in the workplace, the resources of the INRS, and the tightening of regulations on certain CBD products, companies must now distinguish between what constitutes "well-being" communication and what relates to fitness, alertness, and safety. For both employers and employees, the lines are clearly shifting.
Hemp for wellness can no longer be treated as a trivial matter
For several years, hemp products benefited from a relatively positive image: oils, infusions, flowers, and resins were often associated with relaxation routines, stress management, or improved personal balance. In the corporate world, this perception sometimes encouraged informal initiatives: recommendations among colleagues, occasional reimbursements, corporate gifts, or participation in wellness programs.
However, the context of 2025-2026 shows that this interpretation has become too simplistic. In 2025, ANSES proposed classifying cannabidiol as a suspected toxicant for human reproduction in category 1B. Even though this proposal is part of an evaluation process and does not in itself constitute a general ban, it profoundly alters how a prudent organization must analyze the use of hemp-based products.
For a company's well-being policy, this changes everything. As soon as a product is no longer perceived as toxicologically neutral, it becomes difficult to promote it without reservation. The issue moves from the realm of lifestyle to that of precaution, honest information, and risk assessment, particularly when it concerns employees exposed to safety, vigilance, or reproductive health constraints.
Why the ANSES alert changes the game
The central point of ANSES's report rests on toxicological data that cannot be dismissed out of hand. The agency relies in particular on animal studies showing possible effects on spermatogenesis, fertility, perinatal mortality, and neurodevelopment. In other words, CBD is no longer simply viewed as a "non-euphoric" compound, but also as a substance that warrants a genuine cautionary approach.
For companies, the stakes are very real. A sound HR policy must consider how to communicate about a product that may be used by employees planning for parenthood, pregnant, or in positions where maintaining peak alertness is essential. Even without definitive conclusions on all uses, the mere fact that a public body has issued this alert level necessitates a review of messaging and practices.
This doesn't mean that all hemp products are equal or that they all present the same risk profile. On the contrary, this is precisely why we need to move beyond vague slogans. The difference between a legal product, lab-tested and properly labeled, and an item of uncertain origin containing undesirable substances can be significant. But in a professional context, this distinction demands greater rigor, not less.
Occupational health is regaining control over psychoactive substances
Another important development: in 2025, the HAS (French National Authority for Health) issued a recommendation on the use of psychoactive substances in the workplace. The stated objectives are clear: to identify work-related addiction problems, reduce use, and prevent accidents. Crucially, the recommendation explicitly targets employers, employees, managers, and trainees, demonstrating that prevention is becoming a shared responsibility.
In this context, hemp-based solutions can no longer be considered in isolation from other prevention policies. Even when a product is legal, its place within the company depends on its potential impact on behavior, alertness, adherence to safety guidelines, and the clarity of internal rules. An organization cannot support a psychoactive substance prevention strategy while maintaining complete ambiguity regarding the use of CBD products during working hours.
The HAS also emphasizes that prevention is not limited to immediate accidents. It also aims to integrate support for workers with substance abuse or addiction into the strategy for preventing job loss due to health issues. In practice, this encourages companies to adopt a more structured, humane, and medically sound approach to the subject, moving away from hasty judgments and excessive marketing rhetoric.
Well-being and fitness for work: a boundary to be clarified
One of the major challenges of HR policy is clearly distinguishing between personal well-being and work fitness. Just because a product is perceived as relaxing outside the workplace doesn't mean it's suitable for all professional contexts. Positions involving driving, handling, working at heights, operating machinery, dealing with sensitive customer interactions, or making quick decisions demand a level of attention incompatible with any gray area regarding vigilance.
In France, occupational medicine and occupational health and safety services remain central to employee monitoring. It is within this framework that issues related to hemp, CBD, and more broadly, psychoactive substances, must be assessed. A responsible company does not transform a medical and preventative issue into a mere employer branding tool.
In practical terms, this means that internal policies must be clear: what does the regulation or charter say about the use of CBD products before or during work? How are employees informed about the risks, interactions, uncertainties, and situations incompatible with certain positions? And who should someone be referred to if they express a difficulty, a health question, or a need for support?
INRS and the institutional rapprochement between cannabis, CBD and work
The French institutional framework is also becoming more explicit. The INRS (National Institute for Research and Safety) points out that cannabis is the most commonly used illicit substance in the workplace and provides prevention tools for occupational health professionals. Even though CBD does not have the same legal status as illicit cannabis, their similar image and use are now leading to more careful consideration in internal policies.
This convergence is important because it forces employers to avoid oversimplification. On the one hand, not every hemp-based product should be automatically equated with illicit use. On the other hand, it would be unwise to ignore the real difficulties in distinguishing between products in practice, particularly when products may contain traces of THC, be mislabeled, or circulate without sufficient guarantees. Prevention efforts must therefore be nuanced, yet firm.
For managers and HR teams, this requires a pedagogical effort. They must explain the differences in status, composition, and risk, without trivializing the practices. It's also crucial to remember that, within the company, the key question isn't just "is it legal?", but also "is it compatible with safety, health, and professional obligations?" This is often where the real decision lies.
The growing problem of poisoning and non-compliant products
Since 2024, ANSES (the French Agency for Food, Environmental and Occupational Health & Safety) has reported a significant increase in poisonings linked to CBD products in France. This point is crucial in the debate on workplace well-being, as it demonstrates that the risk stems not only from cannabidiol itself, but also from the actual quality of the products on the market. In many cases, poisonings are linked to the presence of THC or unwanted synthetic cannabinoids.
In other words, product compliance becomes an indirect HR issue. A company that distributes, recommends, or reimburses hemp-based solutions without verifying their traceability risks reputational, legal, and health-related damage. For employees, the promise of a “natural” or “light” product can mask poorly controlled compositions, particularly in markets where controls are tightening but the product range remains highly heterogeneous.
This is precisely why laboratory-tested, legally compliant, and clearly documented products play a key role in the sector's maturity. When discussing hemp in a serious context, quality isn't a secondary marketing argument; it's fundamental. From a business perspective, prudence dictates prioritizing transparent information, certificates of analysis, and reliable supply chains over vague promises or unjustifiably attractive prices.
French and European regulations remain demanding
French regulations remain strict regarding CBD products. In 2026, the French Ministry of Agriculture reiterated that certain CBD-containing products may be considered illegal depending on their intended use as food. For its part, the EFSA (European Food Safety Authority) maintains its reservations about the safety of CBD as a novel food. For businesses, this means that a product available online or in stores is not automatically compatible with their internal distribution or refund policies.
This reality directly impacts workplace well-being strategies . Management wishing to include hemp-based products in employee benefits packages, prevention budgets, or quality of work life (QWL) programs must consider much more than just the product's image. They must verify the regulatory category, the claimed use, the manufacturer's documentation, analyses, labeling, and the risk of reclassification depending on the method of presentation or consumption.
The 2026 trend confirms that hemp for wellness is becoming as much a product compliance issue as an HR one. Stricter controls can affect not only sellers but also organizations that distribute certain products without sufficient due diligence. In short, good intentions don't protect against poor supplier selection.
Towards more coherent and realistic corporate policies
Faced with these developments, companies have a vested interest in developing simple, consistent, and applicable policies. First rule: do not confuse supporting well-being with implicitly validating consumption in the workplace or during working hours. Second rule: integrate the issue of cannabis into the broader policy for preventing psychoactive substances. Third rule: rely on competent stakeholders, particularly occupational health services, prevention services, and safety officers.
A realistic approach also means avoiding extreme positions. Neither complete trivialization nor automatic dramatization. Not all employees consume the same products, for the same purposes, nor with the same consequences. But the company itself must base its decisions on its obligations regarding safety, health protection, social dialogue, and compliance. This foundation allows for the establishment of credible rules.
For players in the hemp and CBD sector, this phase also presents an opportunity for professionalization. As discussions about CBD in the workplace become more structured, consumers increasingly expect clean, analyzed, traceable, and compliant products. In a market sometimes clouded by dubious offerings, transparency becomes a tangible advantage for adults seeking legal, reliable, and better-regulated solutions.
Ultimately, the question is no longer whether hemp-based solutions have a place in discussions about workplace well-being. They already do, but this place is now framed by broader issues: occupational health, vigilance, risk prevention, product quality, and legal security. In 2025-2026, the discourse is becoming more professional, and that's probably good news for everyone.
For both employers and employees, the best approach remains transparency: reliable information, explicit internal rules, access to occupational health professionals, and the selection of rigorously controlled products when permitted by law. In the hemp industry, as in the corporate world, sustainable well-being relies less on empty promises than on trust, compliance, and responsibility.
